Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide

Genmab A/S OMXCOP:GMAB:

• ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EPCORITAMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL

• EPCORE DLBCL-4 REDUCES RISK OF PROGRESSION AND DEATH BY UP TO 60%

• REPORTS PHASE 3 EPCORE DLBCL-4 TRIAL MEETS PRIMARY ENDPOINT IN R/R DLBCL

• EPCORITAMAB PLUS LENALIDOMIDE SHOWS CONSISTENT SAFETY PROFILE

• CO AND ABBVIE TO ENGAGE REGULATORY AUTHORITIES ON EPCORE DLBCL-4 RESULTS